Table Graph
   

potential COVID-19 treatments - versus placebo - for COVID-19 severe or critically pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.76 [0.61, 0.95]< 113%12 studies (12/-)99.2 %some concernlow moderatecrucial-
death or transfer to ICU 0.65 [0.35, 1.22]< 10%1 study (1/-)90.9 %NAnot evaluable crucial-
deaths 0.78 [0.64, 0.95]< 113%17 studies (17/-)99.3 %some concernlow moderatecrucial-
deaths (time to event analysis only) 0.86 [0.65, 1.14]< 131%7 studies (7/-)84.8 %some concernnot evaluable moderatecrucial-
clinical deterioration 0.94 [0.57, 1.55]< 10%2 studies (2/-)59.8 %lownot evaluable highimportant-
clinical improvement 1.09 [0.96, 1.23]> 113%10 studies (10/-)90.6 %some concerncritical moderateimportant-
clinical improvement (14-day) 1.18 [0.84, 1.66]> 134%3 studies (3/-)82.9 %some concernnot evaluable moderateimportant-
clinical improvement (28-day) 1.35 [1.04, 1.76]> 10%6 studies (6/-)98.7 %lowserious highimportant-
clinical improvement (7-day) 0.99 [0.18, 5.51]> 10%1 study (1/-)49.4 %NAnot evaluable important-
clinical improvement (time to event analysis only) 1.04 [0.95, 1.14]> 10%7 studies (7/-)81.9 %some concernserious moderateimportant-
death or ventilation 0.76 [0.49, 1.16]< 147%3 studies (3/-)89.9 %some concernnot evaluable moderateimportant-
hospital discharge 1.04 [0.90, 1.21]> 10%4 studies (4/-)70.7 %some concernnot evaluable moderateimportant-
mechanical ventilation 0.79 [0.56, 1.11]< 10%7 studies (7/-)91.2 %some concernnot evaluable moderateimportant-
mechanical ventilation (time to event analysis only) 0.81 [0.27, 2.42]< 10%1 study (1/-)64.7 %NAnot evaluable important-
ICU admission 0.57 [0.36, 0.91]< 10%2 studies (2/-)99.1 %some concernnot evaluable moderatenon important-
off oxygenation 0.98 [0.64, 1.51]> 10%1 study (1/-)46.4 %NAnot evaluable non important-
recovery 1.57 [0.77, 3.20]> 10%1 study (1/-)89.3 %NAnot evaluable non important-

safety endpoints 00

AE leading to drug discontinuation 2.43 [0.79, 7.45]< 10%1 study (1/-)6.0 %NAnot evaluable important-
related AE (TRAE) 1.26 [0.14, 11.07]< 10%2 studies (2/-)41.9 %some concernnot evaluable moderateimportant-
serious adverse events 0.91 [0.74, 1.11]< 17%8 studies (8/-)82.7 %some concernnot evaluable moderateimportant-
superinfection 0.81 [0.49, 1.34]< 10%1 study (1/-)79.2 %NAnot evaluable important-
adverse events 1.08 [0.83, 1.39]< 113%7 studies (7/-)28.4 %some concernserious moderatenon important-
deep vein thrombosis 0.50 [0.03, 8.10]< 10%1 study (1/-)68.5 %NAnot evaluable non important-
elevated liver enzymes 0.36 [0.13, 1.01]< 10%1 study (1/-)97.3 %NAnot evaluable non important-
hyperbilirubinemia 1.09 [0.42, 2.79]< 10%1 study (1/-)43.1 %NAnot evaluable non important-
pulmonary embolism 0.50 [0.03, 8.10]< 10%1 study (1/-)68.5 %NAnot evaluable non important-
renal impairment 1.01 [0.03, 30.33]< 10%1 study (1/-)49.9 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons